Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally-Advanced Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00867009
What this trial is testing

Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Eli Lilly and Company 113
Testing effectiveness (Phase 2)Looking for participantsNCT07231068
What this trial is testing

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd. 153
Testing effectiveness (Phase 2)Looking for participantsNCT05442060
What this trial is testing

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
OBI Pharma, Inc 60
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Large-scale testing (Phase 3)UnknownNCT03849768
What this trial is testing

Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Who this might be right for
Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 429
Testing effectiveness (Phase 2)Study completedNCT01204697
What this trial is testing

Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 74
Large-scale testing (Phase 3)Ended earlyNCT00234468
What this trial is testing

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Who this might be right for
Non Small Cell Lung Carcinoma
AstraZeneca 490
Testing effectiveness (Phase 2)Active Not RecruitingNCT03999710
What this trial is testing

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerLung CancerNsclc+2 more
Memorial Sloan Kettering Cancer Center 61
Testing effectiveness (Phase 2)Looking for participantsNCT07058519
What this trial is testing

Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Who this might be right for
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 250
Not applicableLooking for participantsNCT05010109
What this trial is testing

Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation

Who this might be right for
Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+2 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Early research (Phase 1)Study completedNCT03801902
What this trial is testing

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Who this might be right for
Locally Advanced Lung Non-Small Cell CarcinomaLocally Recurrent Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8+2 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07661173
What this trial is testing

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Anhui Provincial Cancer Hospital 154
Testing effectiveness (Phase 2)Study completedNCT03822351
What this trial is testing

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Who this might be right for
Stage III Non-small Cell Lung CancerUnresectable
MedImmune LLC 189
Testing effectiveness (Phase 2)Looking for participantsNCT04198766
What this trial is testing

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Who this might be right for
Solid TumorNon-Small Cell Lung CancerHead and Neck Cancer+5 more
Inhibrx Biosciences, Inc 340
Testing effectiveness (Phase 2)Study completedNCT00115518
What this trial is testing

Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Heidelberg University 30
Early research (Phase 1)Ended earlyNCT05631574
What this trial is testing

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Who this might be right for
Non Small Cell Lung CancerPancreatic CancerColorectal Cancer+14 more
Biomea Fusion Inc. 13
Testing effectiveness (Phase 2)Looking for participantsNCT07087223
What this trial is testing

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute 42
Early research (Phase 1)Looking for participantsNCT07232420
What this trial is testing

BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

Who this might be right for
Non Small Cell Lung CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010
What this trial is testing

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Gruppo Oncologico Italiano di Ricerca Clinica 33
Next Page